Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: A systematic review

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 1031-1040

  Hilleman, Daniel ^a   Campbell, Jennifer ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Alteplase; Hemodialysis catheters; Renal dialysis; Reteplase; Tenecteplase; Thrombolytic agents

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; RETEPLASE; TENECTEPLASE;

ACUTE HEART INFARCTION; BLEEDING; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; CLINICAL PROTOCOL; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DIALYSIS CATHETER; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TREATMENT FAILURE; EQUIPMENT DESIGN; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HUMAN; IATROGENIC DISEASE; LOW DRUG DOSE; OUTCOME ASSESSMENT; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

CATHETERS, INDWELLING; COST-BENEFIT ANALYSIS; EQUIPMENT FAILURE; FIBRINOLYTIC AGENTS; HUMANS; RENAL DIALYSIS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80053305392     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.10.1031     Document Type: Review

References (44)

1. U.S. Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009
2. National Kidney Foundation. Dialysis outcomes quality initiative (K/DOQI) clinical practice guidelines for vascular access: update 2000. Am J Kidney Disease 2001;37(suppl 1):S137-81.
3. Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A. Clinical practice guidelines for vascular access: Canadian Society of Nephrology. J Am Soc Nephrol 1999;10:S297-305.
4. Dinwiddie LC, Bhola C. Hemodialysis catheter care: current recommendations for nursing practice in North America. Nephrol Nurs J 2010:37:507-21.
5. Mendelssohn DC, Ethier SJ, Saran R, Port FK, Pisoni RL. Hemodialysis vascular access problems in Canada: results from the dialysis outcomes and practice patterns study (DOPPS II). Nephrol Dial Transplant 2005;21:721-8.
6. Arbor Research Collaborative for Health. 2009 annual report of the dialysis outcomes and practice patterns study: hemodialysis data 1999-2008. Ann Arbor, MI: Arbor Research Collaborative for Health, 2009.
7. Boyle MJ, Gawley WF, Hickey DP, et al. Experience using the Quinton Permacath for hemodialysis in the Irish Republic. Nephrol Dial Translpant 1997;12:1934-99.
8. Schnabel KJ, Simons ME, Zevallos GF, et al. Image-guided insertion of the Uldall tunneled hemodialysis catheter: technical success and clinical follow-up. J Vasc Interv Radiol 1997;8:579-86. (Pubitemid 27521497)
9. Little MA, O'Riordan A, Lucey B, et al. A prospective study of complications associated with cuffed, tunneled hemodialysis catheters. Nephrol Dial Transplant 2001;16:2194-200. (Pubitemid 33062143)
10. Trerotola SO, Johnson MS, Harris VJ, et al. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology 1997;203:489-95. (Pubitemid 27176227)
11. National Kidney Foundation. Dialysis outcomes quality initiative: clinical practice guidelines for vascular access. Am J Kidney Dis 1997;30:S152-89.
12. Hartnell GG, Gates J. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States. J Vasc Interv Radiol 2000;11:841-7. (Pubitemid 30485095)
13. Welik RA, Josselson J, Shen SY, Reed WR, Sadler JH. Repeated low-dose streptokinase infusions into occluded permanent, central-venous, hemodialysis catheters. Kidney Int 1987;31:1210-12. (Pubitemid 17069107)
14. U.S. Food and Drug Administration. Important drug warning, streptokinase. Letter from Center for Biologics Evaluation and Research, Public Health Service. Rockville, MD: Food and Drug Administration, 1999.
15. Genentech Inc. Cathflo Activase (alteplase) prescribing information. Available from http://www.gene.com/gene/products/information/pdf/cathflo- prescribing.pdf. Accessed April 12, 2011.
16. Destination Rx. Drug cost information for Cathflow Activase (alteplase). Available from http://drugcompare.destinationrx.com/Drug Information.aspx. Accessed April 12, 2011.
17. Genentech Inc. A study of tenecteplase for restoration of function in dysfunctional hemodialysis catheters (TROPICS 4). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/ show/ NCT00396253. Accessed November 2, 2010.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. JAMA 2000;283:2008-12. (Pubitemid 30214957)
19. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376-80. (Pubitemid 27102522)
20. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997;127:380-7. (Pubitemid 27362747)
21. Centocor, Inc. Data on file. Malvern, PA; 2000.
22. Meers C, Toffelmire EB. Tissue plasminogen activator (t-PA) efficacy in the restoration of hemodialysis catheter function. CANNT J 1999;9:25-8.
23. Daeihagh P, Jordan J, Chen GJ, Rocco M. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 2000;36:75-83.
24. Savader SJ, Ehrman KO, Porter DJ, Haikal LC, Oteman AC. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures. J Vasc Intervent Radiol 2001;12:711-15. (Pubitemid 32521159)
25. Spry LA, Miller G. Low-dose tPA for hemodialysis catheter clearance. Dial Transplant 2001;30:1250-4.
26. Eyrich H, Walton T, Macon EJ, Howe A. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Pharm 2002;59:1437-40.
27. Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM. Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother 2003;37:27-33. (Pubitemid 36068594)
28. Davies J, Casey J, Li C, Crowe AV, McClelland P. Restoration of flow following haemodialysis catheter thrombus: analysis of rt-PA infusion in tunneled dialysis catheters. J Clin Pharm Ther 2004;29:517-20. (Pubitemid 40007078)
29. Nguyen TV, Dikun M. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis. Am J Health Syst Pharm 2004;61:1922-4. (Pubitemid 39481346)
30. O'Mara NB, Ali S, Bivens K, Shermann RA, Kapoian T. Efficacy of tissue plasminogen activator for thrombolysis in central venous dialysis catheters. Hemodial Int 2003;7:130-4.
31. MacRae JMLG, Djurdjev O, Shalansky S, Werb R, Levin A, Kiaii M. Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodial Int 2005;9:189-95. (Pubitemid 40932766)
32. Hammond J, Shalansky K, Jastrzebski J. Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions. J Vasc Access 2005;6:72-82.
33. Paulsen D, Reisaether A, Aasen M, Fauchald P. Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 1993;64:468-70. (Pubitemid 23202861)
34. Castner D. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nephrol Nurs J 2001;28:403-10.
35. Hilleman DE, Dunlay RW, Packard KA. Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 2003;23:137-41. (Pubitemid 36197452)
36. Falk A, Samson W, Uribarri J, Vassalotti JA. Efficacy of reteplase in poorly functioning hemodialysis catheters. Clin Nephrol 2004;61:47-53. (Pubitemid 38100843)
37. Hyman G, England M, Kibede S, Lee Willets G. The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center. Nephrol Clin Pract 2004;96:c39-42.
38. Tumlin J, Goldman J, Spiegel DM, et al. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPIC 3. Clin J Am Soc Nephrol 2010;5:631-8.
39. Fishbane S, Milligan SL, Lempert KD, et al. Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study - TROPICS 4. J Thromb Thrombolysis 2010;30:1-8.
40. Hilleman DE, Tsikouris JP, Seals AA, Marmur JD. Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy 2007;27:1558-70. (Pubitemid 350060210)
41. Genentech, Inc. Activase (intravenous alteplase) prescribing information. Available from http://www.gene.com/gene/products/information/pdf/activase- prescribing.pdf. Accessed April 12, 2011.
42. Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis Proteolysis 1997;11:129-35.
43. Melzer C, Richter C, Rogalla P, et al. Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis 2004;18:47-50. (Pubitemid 40361649)
44. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.